Ronald E. Blaylock, Director at PFIZER INC (PFE), bought 39,231 shares at $25.46 ($999K) on 2026-08-05, disclosed to the SEC on 2026-08-05.
Pfizer Director Ronald Blaylock purchased $998,821 worth of stock at $25.46, marking the largest insider purchase in the company's history and signaling confidence in the stock's value. This significant buy comes as the stock has recently rebounded 8.64% over the past 30 days.
Pfizer shares are currently trading at $25.79, up 2.5% over the last five days and 8.64% over the past month, but remain 10.25% below the 52-week high of $28.74.
1) Q2 earnings on August 14, 2026, as noted in Barrons.com; 2) A $44 million settlement for Chantix lawsuits announced on August 13, 2026, which could impact legal costs; 3) The company is paying $19 billion to BioNTech, a significant financial commitment.
1) The stock is down approximately 28% over the past five years, as noted in Simply Wall St.; 2) The recent surge in insider buying follows a mixed set of valuation checks, as noted in Simply Wall St.
Something here stands out, but not much.
| Filing → |
| PFE | BUY | 2020-08-10 | $617K | — | Filing → |
| KMX | SELL | 2020-07-15 | $912K | — | Filing → |
| ROIA | SELL | 2015-09-25 | $25K | — | Filing → |